The ADHD franchise is growing strongly and now represents 36% of revenue, partially offsetting the declining pain portfolio. Monitor whether the pain portfolio erosion accelerates and whether AZSTARYS can sustain prescription growth beyond the initial acquisition quarter. The reaffirmed guidance suggests management sees no material change in full-year expectations.
Drug in focus
COLL drug pipeline →Nucynta ER
● Neutral Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already on the market — approved since 2008 (IR) and 2011 (ER)
- Next catalyst
- None dated
What to watchNucynta ER itself is not a catalyst for COLL. The stock's next binary event is Q3 2026 earnings on November 5, 2026, where the market will focus on guidance for the integrated portfolio including the AZSTARYS acquisition. Investors should watch for Nucynta's ongoing revenue erosion from generic tapentadol, and whether Collegium's ADHD pivot can offset pain-portfolio declines to justify the analyst consensus ~$49 target.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $25.16entry
- T+1 · 11d ago −3.78%α −4.09% · $24.21
- T+5 · 5d ago −0.83%α −4.13% · $24.95
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Collegium reported Q3 2026 revenue of $216.3M (up 3% YoY, in line with $216.0M consensus) and adjusted EPS of $1.96 (above the $1.86 consensus, a beat of 5.4%). ADHD franchise grew to 36% of revenue with JORNAY PM up 24% YoY, but the pain portfolio declined 18% YoY. GAAP net income fell to $21.8M from $31.5M a year ago, and adjusted EBITDA declined 9% to $121.6M. Full-year 2026 guidance was reaffirmed.
Key Financial Metrics
Key Facts
- Q3 2026 product revenue $216.3M, up 3% YoY from $209.4M
- Adjusted EPS $1.96 vs consensus $1.86 (beat by 5.4%)
- GAAP diluted EPS $0.60 vs $0.84 a year ago
- JORNAY PM revenue $51.9M, up 24% YoY; AZSTARYS revenue $26.5M in first full quarter under Collegium ownership
- Pain portfolio revenue $138.0M, down 18% YoY
- Adjusted EBITDA $121.6M, down 9% YoY from $133.0M
- Full-year 2026 guidance reaffirmed: product revenue $825-$855M, adjusted EBITDA $445-$470M
- Announced $50M accelerated share repurchase program in Q3 2026
Financial Impact
Revenue in line with consensus; adjusted EPS beat by $0.10 (5.4%); GAAP net income declined 31% YoY; adjusted EBITDA down 9% YoY
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| JORNAY PM | $51.9M | +24.0% |
| AZSTARYS | $26.5M | Not reported |
| Pain Portfolio | $138.0M | -18.0% |
| Belbuca | $57.7M | -1.0% |
| Xtampza ER | $45.8M | -9.0% |
| Nucynta Franchise | $30.8M | -44.0% |
Risk Factors
- Pain portfolio declining 18% YoY with Nucynta franchise down 44%
- GAAP net income fell 31% YoY due to higher operating expenses and acquisition-related costs
- Adjusted EBITDA declined 9% YoY despite revenue growth
- Debt increased to $842.5M in term notes from $571.1M at year-end 2025 due to AZSTARYS acquisition financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3396299 |
Track record
24 reports on COLL
1 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +0.28% at T+1 after the Aug 13, 2026 report. 1 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $25.68 Now $25.43 −0.97% settles Nov 17
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $24.47 to $24.81 Now $25.43 +3.92% ▲ +1.39% +0.07% vs SPY
- Nov 9, 20267d ago Institutional Cluster Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Viewing Entry $25.16 to $24.21 Now $25.43 +1.07% ▼ −3.78% −4.09% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $23.80 to $23.68 Now $25.43 +6.85% ▼ −0.50% −0.03% vs SPY
- Oct 29, 202618d ago SC 13G/A Neutral 3/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 29, 202618d ago Press Release Neutral 2/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $23.50 to $22.96 Now $25.43 +8.21% ▼ −2.30% −1.78% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers